Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Invested Capital (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Invested Capital for 9 consecutive years, with $500.1 million as the latest value for Q4 2025.

  • For Q4 2025, Invested Capital changed N/A year-over-year to $500.1 million; the TTM value through Dec 2025 reached $500.1 million, changed N/A, while the annual FY2025 figure was $500.1 million, N/A changed from the prior year.
  • Invested Capital hit $500.1 million in Q4 2025 for Soleno Therapeutics, up from $494.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $500.1 million in Q4 2025 and bottomed at $232.3 million in Q1 2025.